New Alzheimer's drug shows promise in early trial
NCT ID NCT06774261
First seen Jun 01, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This early-phase study tested whether phenserine, a new drug, could help people with early or mild Alzheimer's disease. Sixteen participants took either phenserine or the standard drug donepezil for 8 weeks. Researchers measured blood markers of cell death, brain cell health, and inflammation to see if phenserine works differently than donepezil.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stavanger University Hospital
Stavanger, Norway
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.